AMARIN CORP PLCUK (AMRN): restructuring charge — Amarin licenses VAZKEPA to Recordati in Europe; launches restructuring targeting $70M annual savings

AMARIN CORP PLCUK

Upfront $25M and up to $150M in milestone payments; Recordati to commercialize VAZKEPA in 59 European countries.
Global restructuring to cut operating costs by ~$70M annually; expects $30-37M in restructuring charges in Q2 2025.
Company retains U.S. rights; nearly $300M cash on hand, no debt; accelerated path to positive cash flow.
Agreement term 15 years, auto-renewal subject to commercialization in at least one country.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

AMARIN CORP PLCUK announced a restructuring with charges of between approximately $30 million and $37 million affecting Europe operations.

Type: restructuring
Charge: between approximately $30 million and $37 million
Affected area: Europe operations

Exact text from the filing

On June 24, 2025, as described in the Press Release, the Company announced a global restructuring, with the vast majority of estimated cost savings from reduced commercialization expense from the Company’s Europe operations. The Company expects these actions will reduce operating costs by approximately $70 million annually and is anticipated to be substantially completed by June 30, 2026. Amarin anticipates that it will incur between approximately $30 million and $37 million in charges related to the restructuring, substantially all of which are cash expenditures for one-time termination benefits and associated costs.

View on SEC.gov

Browse all restructurings & charges →

AMARIN CORP PLCUK filing history →

Source: SEC EDGAR

accession 0000950170-25-089218

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.